GlassScriptPhysician profile
Manisha Kochhar
NPI 1366047789
$2,301.06
in general payments reported to CMS, 2019-2025
26 companies · $236 in 2025
The $236 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $301 · 2022: $880 · 2023: $679 · 2024: $206 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,120.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $253.76 | 2022-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $220.89 | 2021-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $196.98 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $180.64 | 2022-2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $177.26 | 2021-2024 | Caplyta |
| Lundbeck LLC | $144.93 | 2021-2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $132.65 | 2021-2025 | Uzedy, Austedo |
| Bausch Health US, LLC | $102.51 | 2022-2025 | Aplenzin |
| Corium, LLC | $87.01 | 2022-2025 | Azstarys, Azstarys |
| Alkermes, INC. | $85.80 | 2022-2023 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $85.63 | 2021-2024 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $79.84 | 2022-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $77.22 | 2022-2023 | Qelbree |
| Axsome Therapeutics, INC. | $70.92 | 2022-2024 | Sunosi, Auvelity |
| Vanda Pharmaceuticals INC. | $61.86 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $60.67 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $58.18 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $55.53 | 2022 | |
| Adlon Therapeutics L.P. | $30.28 | 2021 | |
| Indivior INC. | $27.28 | 2022-2023 | Perseris |
| Sage Therapeutics, LLC | $25.77 | 2021-2022 | |
| Tris Pharma INC | $21.01 | 2023 | Dyanavel Xr |
| Almatica Pharma LLC | $17.53 | 2023 | Venlafaxine, Loreev Xr, Sertraline Hcl |
| Validus Pharmaceuticals LLC | $16.95 | 2022 | |
| Brainsway USA INC | $15.24 | 2023 | |
| Avanir Pharmaceuticals, INC. | $14.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manisha Kochhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.